Drugs / CC100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02050334 | Nov 2013 → Jul 2014 | — | Chemigen, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03049046 Comparator | Apr 2017 → Jan 2018 | amyotrophic lateral sclerosis | Chemigen, LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03049046 ↗ |
| Route | Oral | “given by mouth” NCT02050334 ↗ |